Predict your next investment

HEALTHCARE | Drug Development
pharnext.com

See what CB Insights has to offer

Founded Year

2007

Stage

PIPE | IPO

Total Raised

$20.01M

Market Cap

0.00B

About Pharnext

Pharnext specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.

Pharnext Headquarter Location

11-13 rue René Jacques

Issy-les-Moulineaux, 92130,

France

+33 (0)1 41 09 22 30

Latest Pharnext News

Pharnext : Présentation Corporate de Pharnext

Jan 3, 2022

01/03/2022 | 05:49am EST Message : 2 References herein to this presentation (the "Presentation") shall mean and include this document, any oral presentation accompanying this document provided by Pharnext SA (the "Company") and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this Presentation or attending any meeting where this Presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below: This Presentation is confidential, is intended for the recipient only and thus may not be forwarded, reproduced, redistributed or passed to any other person or published in whole or in part for any purpose. If this document has been received in error, it must be returned immediately to the Company. By receiving this Presentation, you become bound by the above-referred confidentiality obligation. Failure to comply with such confidentiality obligation may result in civil, administrative or criminal liabilities. Recipients of the Presentation should not deal or encourage any other person to deal in the securities of the Company. This Presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transmission, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. No securities of the Company have been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or under any state securities laws, and the securities of the Company may not be offered or sold in the United States (or to, or for the account or benefit of U.S. Persons) except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the U.S. Securities Act. The Company has no current intention to register in the United States any portion of its securities or to conduct a public offering of any of its securities in the United States. No action has been undertaken or will be undertaken to make an offer to the public of securities requiring a publication of a prospectus in the United Kingdom or any member State of the European Economic Area (each a "Relevant State"). As a result, the securities may not and will not be offered in any Member State, except pursuant to Article 1(4) or Article 3(2) of Regulation (EU) 2017/1129 of June 14, 2017 (the "Prospectus Regulation") or under other circumstances not requiring the Company to publish a prospectus pursuant to the Prospectus Regulation and/or the applicable regulations in such Relevant States. For the purposes of this paragraph, "securities offered to the public" in a given Relevant State means a communication to any persons, in any form and by any means, presenting sufficient information on the terms of the offer and the securities to be offered, so as to enable an investor to decide to purchase or subscribe for those securities, as the same may be varied in that Relevant State. This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Growth Paris, including, in particular, the risk factors set out in the Company's annual management report to the shareholders, and in any other periodic report, which are available free of charge on the website of the Company (www.pharnext.fr). Information and other data appearing in such publications, and certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained herein. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular, this document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any contact, commitment or investment decision. The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such information is subject to change at any time. Neither the Company, nor its advisors, nor any other person is under any obligation to update the information, statements or opinions contained in this document. All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of the forward- looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation. Especially in the context of the current health crisis, these risks and uncertainties, include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post marketing data), decisions by regulatory authorities, such as the Food and Drug Admnistration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product and candidates, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. 3

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pharnext

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pharnext is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Dental Health

957 items

Companies delivering dental care products and services. Excludes practice networks.

Pharnext Patents

Pharnext has filed 65 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Analgesics
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/8/2019

3/9/2021

Analgesics, Phenols, Morphinans, Acetylcholinesterase inhibitors, Semisynthetic opioids

Grant

Application Date

7/8/2019

Grant Date

3/9/2021

Title

Related Topics

Analgesics, Phenols, Morphinans, Acetylcholinesterase inhibitors, Semisynthetic opioids

Status

Grant

Pharnext Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pharnext Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.